Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

US job openings in research and development are plunging as the Trump administration ramps up funding cuts to government ...

Merck KGaA's recent stock dip of 13% might scream trouble, but under the hood, things look remarkably solid. Despite a ...

Universal Display appears reasonably valued, and its prospects have improved after its recent blue OLED breakthrough. Read ...

Trump has claimed the move could cut US drug prices by 30 to 80 percent. However, according to German consultancy ...

Merck & Co. got a lukewarm “neutral” rating from Citigroup, along with a price target drop from $115 to $84. Other analysts ...